- Home
- POOL vs IKT Comparison
POOL vs IKT Comparison
Compare POOL & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | POOL | IKT |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 201.3M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | POOL | IKT |
|---|---|---|
| Price | $266.01 | $1.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $312.14 | $6.00 |
| AVG Volume (30 Days) | ★ 723.7K | 685.3K |
| Earning Date | 02-19-2026 | 11-14-2025 |
| Dividend Yield | ★ 1.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 10.93 | N/A |
| Revenue | ★ $5,294,666,000.00 | N/A |
| Revenue This Year | $1.92 | N/A |
| Revenue Next Year | $3.49 | N/A |
| P/E Ratio | $24.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $226.10 | $1.33 |
| 52 Week High | $374.74 | $3.32 |
Technical Indicators
Market Signals| Indicator | POOL | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 63.37 | 52.14 |
| Support Level | $250.06 | $1.57 |
| Resistance Level | $278.17 | $1.72 |
| Average True Range (ATR) | 7.13 | 0.09 |
| MACD | 0.63 | 0.01 |
| Stochastic Oscillator | 74.87 | 83.67 |
Price Performance
Historical ComparisonAbout POOL Pool Corporation
Pool Corp distributes swimming pool supplies and related products. Its products include non-discretionary pool-maintenance products, like chemicals and replacement parts, as well as pool equipment, like packaged pools (kits to build swimming pools), cleaners, filters, heaters, pumps, and lights. Customers include pool builders and remodelers, independent retail stores, and pool repair and service companies.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.